Merck reported strong first-quarter results with growth in core areas like diabetes, vaccines, and oncology, notably with KEYTRUDA's promising performance. The company raised its EPS guidance and showcased positive pipeline developments, suggesting sustained momentum. While there are concerns about biosimilar competition for REMICADE in Europe and FX headwinds, the overall outlook is positive for the short term.

[1]